Earlier Intervention, Lasting Benefit: What VESALIUS-CV Tells Us About Timing and Future Guidelines

A key insight from VESALIUS-CV is how the timing of benefit differs between patients with and without established atherosclerosis. A landmark analysis revealed that while patients with known atherosclerotic disease experienced earlier separation of event curves, those with diabetes but no documented disease saw substantial benefit emerge after approximately one year of treatment—ultimately achieving a 41% risk reduction at that timepoint. This pattern reflects the distinct biological mechanisms at work: in patients with existing plaque, intensive LDL lowering stabilizes and may partially regress atherosclerotic lesions; in patients without established disease, the benefit comes from slowing plaque formation in the first place. The message, in both cases, is that starting sooner yields more cumulative benefit.

The implications for future guidelines are significant. Although the 2026 ACC/AHA dyslipidemia guideline was finalized before the main VESALIUS publication, its recommendations for high-risk diabetic patients—who carry an LDL goal of below 70 mg/dL and may receive high-intensity statins or non-statin add-ons as a class IIa recommendation—are directionally consistent with what VESALIUS demonstrated. The trial's diabetic subgroup achieved LDL levels around 44 mg/dL, suggesting that the sub-70 target may itself be insufficiently ambitious for this population.

The study's safety profile was reassuring over a nearly 5-year follow-up, with no meaningful excess of adverse events in the evolocumab arm. If future guideline iterations incorporate these data, clinicians may see stronger encouragement to pursue PCSK9 inhibition in high-risk primary prevention patients with diabetes—potentially collapsing the distinction between primary and secondary prevention thresholds for this group, and supporting a single, uniformly low LDL target for all high-risk individuals.